Diversified Healthcare Trust
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DHC research report →
Range $8 – $10.5
Price Chart
About the company
Diversified Healthcare Trust (DHC) operates as a real estate investment trust (REIT) specializing in healthcare properties. Its extensive portfolio comprises medical office buildings, life science facilities, senior living communities, and wellness centers located across the United States. DHC's management is provided by an operating subsidiary of The RMR Group Inc.
- CEO
- Christopher J. Bilotto
- IPO
- 2000
- Employees
- 600
- HQ
- Newton, MA, US
Get TickerSpark's AI analysis on DHC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.71B
- P/E
- -11.34
- PEG
- -0.15
- P/S
- 1.19
- P/B
- 1.14
- EV/EBITDA
- 13.33
- Div Yield
- 0.55%
- Gross Margin
- -4.14%
- Op Margin
- -2.09%
- Net Margin
- -10.29%
- ROE
- -9.51%
- ROIC
- -0.74%
Latest fiscal year · YoY change
- Revenue
- $1.54B+2.8%
- Gross Profit
- $-245,333,000-195.7%
- Op Income
- $-39,268,000
- Net Income
- $-285,886,000+22.8%
- EPS
- $-1.19+23.2%
- OCF Growth
- -117.5%
- FCF Growth
- -117.5%
- 52W High
- $9.66
- 52W Low
- $4.34
- 50D MA
- $7.64
- 200D MA
- $7.88
- Beta
- 2.29
- RSI (14)
- 37
- Avg Volume
- 1.81M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Diversified Healthcare Trust posted a strong third quarter with sharply higher SHOP operating performance, raised full-year same-property NOI guidance, and highlighted improving leverage and liquidity.· November 3, 2026
- Normalized FFO was $30.7 million, or $0.13 per share; Adjusted EBITDAre was $73.4 million, up 28.4% year over year.
- Same property cash basis NOI rose 25.6% to $77.9 million, while consolidated NOI increased 27.5% to $80.8 million.
- SHOP was the main driver: same property NOI jumped 50.4% to $48 million, with occupancy up to 84.4% and average monthly rate up 5.2%.
- Management raised 2026 same-property SHOP NOI guidance by $5 million at the midpoint and cut recurring CapEx guidance by $10 million at the midpoint.
- The company said leverage improved to 7.4x excluding incentive fees, liquidity was $261 million, and it expects further improvement from asset optimization and 2027 initiatives.
Reported third quarter 2026 normalized FFO was $30.7 million, or $0.13 per share, and Adjusted EBITDAre was $73.4 million, up 28.4% year over year. Same property cash basis NOI was $77.9 million, up 25.6% year over year, and consolidated NOI was $80.8 million, up 27.5% year over year. SHOP same property NOI increased 50.4% to $48 million, with occupancy at 84.4%, average monthly rate up 5.2%, and margin expanding 470 basis points to 15.8%. Medical office and life science same property cash basis NOI was $22.9 million, down 1.6% year over year. For 2026, the company raised same-property NOI guidance to $312 million to $328 million, Adjusted EBITDAre guidance to $276 million to $291 million, and normalized FFO guidance to $111 million to $126 million, or $0.46 to $0.52 per share. Recurring capital expenditures guidance was reduced to $90 million to $105 million. Management also said fourth quarter will include about $2 million of cash NOI from the Ensign lease, and it has accrued $29.3 million, or $0.12 per share, of estimated incentive management fees in guidance.
Christopher J. Bilotto framed the quarter as evidence that the company’s strategy is working: stronger SHOP operations, asset-by-asset optimization, and improving financial profile. He emphasized occupancy gains, a return to rate growth potential as concessions normalize, and embedded upside from converting closed skilled nursing wings into senior housing units. His tone was confident and forward-looking, especially around 2027 catalysts from the Ensign lease, management agreement changes, and redevelopment projects.
Matthew C. Brown focused on the revised non-GAAP presentation for incentive management fees and quantified the impact: $5.4 million, or $0.02 per share, in Q3 and $22 million, or $0.09 per share, year to date. He said liquidity totaled $261 million, including $111 million of cash and a $150 million undrawn revolver, and net debt to annualized Adjusted EBITDAre was 8.2x, or 7.4x excluding incentive fees, within the target range of 6.5x to 7.5x. He also noted recurring CapEx was reduced to $90 million to $105 million, year-to-date capital spending was $76.5 million, and the company remains comfortably in compliance with bond covenants.
Analysts focused on whether the lower CapEx outlook should be considered a new run rate, with management saying it could decline a little further in 2027 and 2028 and that they are targeting closer to $3 thousand per unit. They also asked whether the full-year guide included the Ensign transaction and whether the raise in SHOP NOI was driven by that deal; management said the Ensign rent was included but was largely a wash versus prior structure, and the guide increase came from stronger SHOP performance. On occupancy versus rate, management said concessions are tactical and not expected to last long term, while redevelopment projects are mostly 2027 starts with only soft costs incurred this year.
The call showed clear operating momentum in SHOP, with occupancy, rate, margin, and NOI all moving in the right direction. Management also pointed to several embedded 2027 drivers already in motion, including the Ensign lease, management agreement savings, unit conversions, and asset sales, while leverage and liquidity continue to improve.
Medical office and life science occupancy fell after tenant move-outs, and management is still working through additional vacancies and dispositions. Near-term guidance also depends on execution on occupancy, concessions, and redevelopment timing, while the company still carries meaningful debt and its incentive fee accrual can affect reported non-GAAP metrics and leverage calculations.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.3%
- Shares Outstanding
- 242.53M
- Float Shares
- 202.00M
of shares held by institutions
253 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 23.84M | ▲ 764.17K |
| Flat Footed LLC | 23.49M | 0 |
| Vanguard Group Inc | 19.77M | ▲ 205.28K |
| Silver Point Capital, L.P. | 15.50M | 0 |
| H/2 Credit Manager LP | 12.82M | ▼ 2.10M |
| Vanguard Portfolio Management LLC | 10.57M | ▼ 20.50K |
| Vanguard Capital Management LLC | 9.70M | ▲ 29.82K |
| State Street Corp | 9.08M | ▲ 80.24K |
| Geode Capital Management, LLC | 7.00M | ▼ 62.19K |
| Davidson Kempner Capital Management LP | 6.41M | ▲ 161.70K |
| Nomura Holdings Inc | 6.28M | ▼ 1.05M |
| Carronade Capital Management, LP | 6.14M | ▲ 870.89K |
Held by 248 ETFs
Biggest fund positions in DHC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 25 | Brown Matthew C. | other | 9,711 |
| Jan 1, 24 | Bilotto Christopher J. | other | 0 |
| Oct 1, 23 | Brown Matthew C. | other | 0 |
| Sep 26, 23 | Hollis Phyllis M. | other | 20,000 |
| Sep 26, 23 | Hollis Phyllis M. | other | 0 |
| Sep 18, 23 | SIEDEL RICHARD W. JR. | other | 7,086 |
| Sep 18, 23 | Francis Jennifer F. | other | 15,839 |
| Sep 13, 23 | Francis Jennifer F. | other | 60,000 |
| Jun 14, 23 | PORTNOY ADAM D. | buy | 2,000,000 |
| Jun 13, 23 | PORTNOY ADAM D. | buy | 1,992,259 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DHC coverage
Recent articles, reports, and earnings notes.
Want a deeper read on DHC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
5 REITs I Would Never Buy, No Matter How Cheap
seekingalpha.com · Nov 10
Diversified Healthcare Trust (DHC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Diversified Healthcare Trust Q3 Earnings Call Highlights
marketbeat.com · Nov 3
Diversified Healthcare (DHC) Q3 FFO and Revenues Lag Estimates
zacks.com · Nov 2
Diversified Healthcare Trust Announces Third Quarter 2026 Results
businesswire.com · Nov 2
Diversified Healthcare Trust (DHC) Set to Announce Earnings on Monday
defenseworld.net · Oct 26
AI Reality Check, Inflation Stress Test
seekingalpha.com · Oct 18
Diversified Healthcare Trust Announces Quarterly Dividend on Common Shares
businesswire.com · Oct 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
